- Home
- PENN vs APLS Comparison
PENN vs APLS Comparison
Compare PENN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PENN
- APLS
- Stock Information
- Founded
- PENN 1972
- APLS 2009
- Country
- PENN United States
- APLS United States
- Employees
- PENN N/A
- APLS N/A
- Industry
- PENN Hotels/Resorts
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- PENN Consumer Discretionary
- APLS Health Care
- Exchange
- PENN Nasdaq
- APLS Nasdaq
- Market Cap
- PENN 2.8B
- APLS 2.9B
- IPO Year
- PENN 1994
- APLS 2017
- Fundamental
- Price
- PENN $13.66
- APLS $20.17
- Analyst Decision
- PENN Buy
- APLS Buy
- Analyst Count
- PENN 18
- APLS 19
- Target Price
- PENN $21.94
- APLS $33.11
- AVG Volume (30 Days)
- PENN 4.0M
- APLS 3.3M
- Earning Date
- PENN 11-06-2025
- APLS 10-30-2025
- Dividend Yield
- PENN N/A
- APLS N/A
- EPS Growth
- PENN N/A
- APLS N/A
- EPS
- PENN N/A
- APLS 0.36
- Revenue
- PENN $6,823,800,000.00
- APLS $1,016,397,000.00
- Revenue This Year
- PENN $8.36
- APLS $25.39
- Revenue Next Year
- PENN $5.50
- APLS N/A
- P/E Ratio
- PENN N/A
- APLS $56.21
- Revenue Growth
- PENN 8.24
- APLS 42.11
- 52 Week Low
- PENN $13.24
- APLS $16.10
- 52 Week High
- PENN $23.08
- APLS $35.72
- Technical
- Relative Strength Index (RSI)
- PENN 30.96
- APLS 41.04
- Support Level
- PENN $13.45
- APLS $19.40
- Resistance Level
- PENN $14.56
- APLS $20.70
- Average True Range (ATR)
- PENN 0.84
- APLS 0.71
- MACD
- PENN -0.08
- APLS 0.05
- Stochastic Oscillator
- PENN 10.17
- APLS 71.72
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media assets, theScore and ESPN (starting with its partnership launch in November 2023), provide access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.